The starting line
A 20% share of the US market. Less than 10% across international regions. A commercial model that was not translating abroad.
The US-based manufacturer had established a strong domestic position in metabolic and cardiovascular medical devices, including stents, pacemakers and defibrillators. It held 20% market share in the US and had begun expanding internationally in 2008. Yet its share across international regions remained below 10%. The business needed a more effective way to compete across markets with different commercial conditions and procurement requirements.
International contracting relied heavily on manual processes and a US-centric approach. Teams lacked a consistent way to identify and prioritize opportunities across markets. In indirect markets, they relied on distributors for local market information, making it difficult to independently assess contract opportunities, market conditions and competitor activity. Pricing decisions were difficult to calibrate against historical performance and evolving market conditions. The initial contract win rate was 14%, with margin losses reaching up to 40%.
The company had the products and the ambition to grow internationally. What it lacked was the data foundation and commercial intelligence to identify the right opportunities, respond effectively and compete without surrendering unnecessary margin.
2008
Start of international expansion
Below 10%
Market share across international regions
14%
Initial contract win rate
Up to 40%
Contract margin loss
The commercial consequences were visible in the numbers: a 14% contract win rate and margin loss of up to 40%. The business needed to improve both sides of the contract decision: which opportunities to pursue and how to price them.
We had built a strong position in the US, but we didn't have the same level of visibility across our international markets. We needed better intelligence to understand where to compete and how to price our contracts.
— Head of Commercial Excellence (role anonymized)